T. Rowe Price Associates
AVXL icon

T. Rowe Price Associates’s Anavex Life Sciences AVXL Stock Holding History

T. Rowe Price Associates’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$195K Buy
63,226
+16,947
+37% +$73.4K ﹤0.01% 2853
2025
Q4 		$165K Buy
46,279
+669
+1% +$4.1K ﹤0.01% 2852
2025
Q3 		$406K Buy
45,610
+3,838
+9% +$38.9K ﹤0.01% 2455
2025
Q2 		$386K Buy
41,772
+8,733
+26% +$74.5K ﹤0.01% 2421
2025
Q1 		$284K Buy
33,039
+3,842
+13% +$36.3K ﹤0.01% 2493
2024
Q4 		$314K Sell
29,197
-33,912
-54% -$261K ﹤0.01% 2490
2024
Q3 		$359K Buy
63,109
+9,314
+17% +$53.7K ﹤0.01% 2399
2024
Q2 		$228K Buy
53,795
+2,021
+4% +$8.18K ﹤0.01% 2541
2024
Q1 		$264K Buy
51,774
+946
+2% +$5.33K ﹤0.01% 2491
2023
Q4 		$474K Buy
50,828
+1,319
+3% +$9.08K ﹤0.01% 2196
2023
Q3 		$325K Buy
49,509
+6,140
+14% +$48.9K ﹤0.01% 2299
2023
Q2 		$353K Buy
43,369
+875
+2% +$7.5K ﹤0.01% 2286
2023
Q1 		$365K Buy
42,494
+427
+1% +$4.26K ﹤0.01% 2250
2022
Q4 		$390K Buy
42,067
+626
+2% +$6.69K ﹤0.01% 2260
2022
Q3 		$428K Buy
41,441
+4,480
+12% +$47.3K ﹤0.01% 2203
2022
Q2 		$370K Buy
36,961
+509
+1% +$4.82K ﹤0.01% 2349
2022
Q1 		$449K Buy
36,452
+4,747
+15% +$58.4K ﹤0.01% 2386
2021
Q4 		$550K Buy
31,705
+664
+2% +$12.6K ﹤0.01% 2343
2021
Q3 		$557K Buy
31,041
+9,900
+47% +$197K ﹤0.01% 2335
2021
Q2 		$483K Sell
21,141
-501
-2% -$7.42K ﹤0.01% 2405
2021
Q1 		$324K Sell
21,642
-44,350
-67% -$484K ﹤0.01% 2539
2020
Q4 		$356K Sell
65,992
-24,100
-27% -$127K ﹤0.01% 2368
2020
Q3 		$410K Sell
90,092
-70
-0.1% -$301 ﹤0.01% 2175
2020
Q2 		$444K Sell
90,162
-24,714
-22% -$93.4K ﹤0.01% 2093
2020
Q1 		$362K Buy
114,876
+84,700
+281% +$295K ﹤0.01% 2126
2019
Q4 		$78K Buy
30,176
+1,701
+6% +$4.46K ﹤0.01% 2474
2019
Q3 		$90K Buy
28,475
+196
+0.7% +$566 ﹤0.01% 2460
2019
Q2 		$95K Buy
28,279
+810
+3% +$2.52K ﹤0.01% 2485
2019
Q1 		$84K Buy
27,469
+741
+3% +$1.77K ﹤0.01% 2481
2018
Q4 		$42K Sell
26,728
-29,200
-52% -$66.3K ﹤0.01% 2533
2018
Q3 		$153K Buy
55,928
+271
+0.5% +$764 ﹤0.01% 2496
2018
Q2 		$146K Buy
55,657
+50
+0.1% +$140 ﹤0.01% 2496
2018
Q1 		$153K Buy
55,607
+373
+0.7% +$1.05K ﹤0.01% 2451
2017
Q4 		$178K Buy
55,234
+1,086
+2% +$4.27K ﹤0.01% 2442
2017
Q3 		$224K Buy
54,148
+626
+1% +$2.78K ﹤0.01% 2376
2017
Q2 		$285K Buy
53,522
+237
+0.4% +$1.37K ﹤0.01% 2260
2017
Q1 		$306K Buy
53,285
+23,500
+79% +$121K ﹤0.01% 2253
2016
Q4 		$118K Hold
29,785
– – ﹤0.01% 2456
2016
Q3 		$108K Buy
+29,785
New +$125K ﹤0.01% 2436

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $7.85B AUM 20.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

T. Rowe Price Associates's AVXL Position: Q1 2026 in Review

T. Rowe Price Associates increased its Anavex Life Sciences (AVXL) stake by 37% in Q1 2026, buying an estimated $73.4K and bringing the position to 63,226 shares worth $195K. The position accounts for ﹤0.01% of the portfolio, ranked #2853.

T. Rowe Price Associates first reported a position in AVXL in Q3 2016 and has held it in 39 quarters since. The position peaked at $557K in Q3 2021. 190 funds tracked by Wall St. Rank hold AVXL as of Q1 2026.

  • T. Rowe Price Associates held 63,226 shares of Anavex Life Sciences worth $195K as of Q1 2026.
  • T. Rowe Price Associates bought 16,947 Anavex Life Sciences shares in Q1 2026, an estimated $73.4K.
  • Anavex Life Sciences made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2853 holding.
  • T. Rowe Price Associates first reported a position in Anavex Life Sciences in Q3 2016 and has held it in 39 quarters since.
  • T. Rowe Price Associates's Anavex Life Sciences position peaked at $557K in Q3 2021.
  • 190 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.